Kansas City, KSNCT06343805Now EnrollingIRB Ready

Primary Myelofibrosis Clinical Trial in Kansas City, KS

Access cutting-edge primary myelofibrosis treatment through this clinical trial at a research site in Kansas City. Study-provided care at no cost to qualified participants.

Sponsored by Ajax Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Kansas City location

Preparing your pre-screening questions…

Expert Care in Kansas City

Access primary myelofibrosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related primary myelofibrosis treatment provided free

Apply for This Kansas City Location

Check if you qualify for this primary myelofibrosis clinical trial in Kansas City, KS

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Kansas City

    Convenient for KS residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Kansas City site if eligible
  4. 4Begin participation

About This Primary Myelofibrosis Study in Kansas City

AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II JAK2 inhibitor, AJ1-11095, in subjects with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.

Sponsor: Ajax Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

18 years of age or older.
Diagnosis of PMF, post-PV MF, or post-ET MF.
DIPSS Intermediate-2 or High-risk MF with ≤10% blasts, regardless of JAK2 mutation status.
Estimated spleen volume ≥450cm3.
MFSAF v.4.0 TSS ≥10, or at least 2 of 7 MFSAF-assessed symptoms with scores ≥3.
ECOG PS of 0, 1, 2, or 3.
Prior therapy with at least 1 type I JAK2 inhibitor, and either failed to achieve a response or relapsed after achieving a response.
ANC ≥1.0×10\^9/L.
Platelet count ≥75×10\^9/L.
eGFR ≥45 mL/min/1.73m2.
Serum total bilirubin ≤2.0 × upper limit of normal (ULN).
AST and ALT ≤3.0 × ULN.
QTcF ≤480 msec.

Exclusion Criteria

Prior splenectomy.
Splenic irradiation within 3 months prior to first dose of study drug.
Ongoing use of systemic corticosteroids at dose equivalent to \>10mg/day of prednisone.
Uncontrolled intercurrent illness such as an acute infection.
Chronic active or acute hepatitis B or C infection.
Chemotherapy in the previous 4 weeks prior to first dose of study drug (Hydrea is permitted until 5 days before starting protocol therapy).
Use of a Type I JAK2 inhibitor must have been discontinued for at least 5 days or 5 half-lives prior to dosing (whichever is longer).
Use of erythropoiesis stimulating agents (unless stable for \>8 weeks).
Peripheral neuropathy ≥ Grade 2 (NCI CTCAE v 5.0).
Unable or unwilling to undergo CT or MRI for spleen size imaging.
Pregnant or breastfeeding.
Requirement for therapy with a medication that is a strong CYP3A4 inhibitor as a concomitant medication.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Kansas City?

Yes, this clinical trial (NCT06343805) has an active research site in Kansas City, KS that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Primary Myelofibrosis Treatment Options in Kansas City, KS

If you're searching for primary myelofibrosis treatment options in Kansas City, KS, this clinical trial (NCT06343805) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Kansas City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced primary myelofibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all primary myelofibrosis clinical trials near you to find additional studies recruiting in your area.

More Myeloproliferative Neoplasms Trials in Kansas City, KS

See all myeloproliferative neoplasms clinical trials recruiting in Kansas City — not just this study.

Browse Myeloproliferative Neoplasms Trials in Kansas City →

Browse More Trials by Condition

Myeloproliferative Neoplasms TrialsFibromyalgia TrialsMyelofibrosis TrialsAll Conditions →

Ready to Join in Kansas City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Kansas City, KS